Rapid infusion of rituximab is well tolerated in children with hematologic, oncologic, and rheumatologic disorders

Traditional administration of rituximab requires careful titration and may involve many hours to minimize the risk of reactions. The objective of this study was to evaluate the safety of rapid infusions of rituximab in a pilot group of children with hematologic, oncologic, and rheumatologic disorder...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2018-01, Vol.65 (1), p.n/a
Main Authors: Bernhardt, M. Brooke, Guzman, Marietta M., Grimes, Amanda, Kirk, Susan, Nelson, Sheryl, Bergsbaken, Jessica, Minard, Charles G., Despotovic, Jenny McDade
Format: Article
Language:English
Subjects:
Adolescent
Adult
Child
Child, Preschool
Children
Female
Hematologic Diseases - drug therapy
Hematology
Humans
immune thrombocytopenia
Immunotherapy
Infant
Male
Monoclonal antibodies
Neoplasms - drug therapy
Oncology
pediatric hematology
Pediatrics
Pilot Projects
Prospective Studies
Rheumatic Diseases - drug therapy
Rituximab
Rituximab - administration & dosage
Rituximab - adverse effects
Targeted cancer therapy
Titration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Traditional administration of rituximab requires careful titration and may involve many hours to minimize the risk of reactions. The objective of this study was to evaluate the safety of rapid infusions of rituximab in a pilot group of children with hematologic, oncologic, and rheumatologic disorders, and to determine the incidence of rate‐related infusion reactions. Twenty patients enrolled in the study. All patients tolerated the rapid infusion of rituximab and no patient had an infusion‐related reaction. We conclude that rapid infusions of rituximab are well tolerated and safe in our pilot group of patients.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.26759